[PDF][PDF] Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 …
S Gourgou-Bourgade, C Bascoul-Mollevi… - J Clin …, 2013 - researchgate.net
S Gourgou-Bourgade, C Bascoul-Mollevi, F Desseigne, M Ychou, O Bouché, R Guimbaud…
J Clin Oncol, 2013•researchgate.netPurpose To compare the quality of life (QoL) of patients receiving oxaliplatin, irinotecan,
fluorouracil, and leucovorin (FOLFIRINOX) or gemcitabine as first-line chemotherapy and to
assess whether pretreatment QoL predicts survival in patients with metastatic pancreatic
cancer.
fluorouracil, and leucovorin (FOLFIRINOX) or gemcitabine as first-line chemotherapy and to
assess whether pretreatment QoL predicts survival in patients with metastatic pancreatic
cancer.
Purpose
To compare the quality of life (QoL) of patients receiving oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) or gemcitabine as first-line chemotherapy and to assess whether pretreatment QoL predicts survival in patients with metastatic pancreatic cancer.
researchgate.net
